To include your compound in the COVID-19 Resource Center, submit it here.

Alexion's eculizumab misses Phase II endpoint

ALXN said that a 117-patient double-blind, placebo-controlled Phase II safety study of eculizumab to

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE